home - Jobs - Other Positions

Notice Board Topics

Archive workshop and seminar slides Professor Peter Karmerman…
News, Videos and Features News

Chronic pain: the search for a killer

Researchers engaging with local communities

Researchers’ discovery of why sunburn hurts reveals possible target for new pain relief drugs

New award funding of LPC

UK researchers tackle pain

Imperial College and the London Pain Consortium partner with a Japanese chemical company to fight chronic pain


Walking on Fire click here


London Pain Consortium: key Discoveries

Reserachers: Pain killers click here

Painstaking research - tackling chronic pain click here

The London Pain Consortium making a difference
Europain consortium receives EU and industry funding and begins five year research into better treatments for chronic pain Europain, a public-private consortium funded by the Innovative Medicines Initiative (IMI), announced today the launch of a five-year research project to understand and improve treatment of chronic pain. The project will receive 6M€ from the IMI as well as 12.5M€ in kind contribution from the European Federation of Pharmaceutical Industries and Associations (EFPIA) over the coming five years.

One in five adults suffers from chronic pain. This constitutes a major cause of long-term sick leave and forced early retirement, placing a great financial burden on both individuals and healthcare systems. Despite extensive research programmes by biopharmaceutical companies and academia, there remains a need for treatments that are more effective and with fewer side-effects.

Europain has established an international team of leading researchers and clinicians from both academia and industry to undertake multidisciplinary translational research. This team aims to increase the understanding of chronic pain mechanisms, help to develop novel analgesics, and develop better biomarkers for pain. Their ultimate goal is to improve the lives of people suffering from chronic pain.

During the five-year project, Europain will undertake a large number of preclinical and clinical studies. The program will be delivered through collaboration between laboratories in the Europain network, sharing resources to improve the value derived from the budget. Results will be made public during and after the project, ensuring that the knowledge created can be widely applied to the development of better therapies for patients suffering from chronic pain.

King’s College London, the managing entity of Europain and the academic lead institution will contribute to both the pre-clinical and clinical aspects of the project. One role will be to study the expression of potential pain mediators in both animal models of pain and samples from patients suffering from chronic pain. The role of novel pain mediators will then be investigated using an array of techniques ranging from cell culture to quantitative sensory testing in humans.

Professor Steve McMahon, who along with Dr Dave Bennett will be running the project at King’s, comments: ‘There are some big questions facing the pain field at the moment and this consortium, drawing on the skills and expertise of both academia and industry, is in a unique position to address them’.

The consortium network involves scientists representing 12 renowned European Universities: King’s College London (Academic lead), University College London, Imperial College London, the University of Oxford, the Christian-Albrechts-University of Kiel, the Medical Faculty Mannheim/Heidelberg University, the Technische Universität München, the Goethe University of Frankfurt, the BG University Hospital Bergmannsheil/Ruhr University Bochum, the University Hospitals of Aarhus, Rigshospitalet Copenhagen, University of Southern Denmark, the SME Neuroscience Technologies from Barcelona, and the research resources and expertise of Europe’s most active pharmaceutical companies working in the field of analgesics, including AstraZeneca (co-ordinator), Boehringer-Ingelheim, Eli Lilly, Esteve, Pfizer, Sanofi-Aventis, UCB Pharma.

About the Innovative Medicines Initiative

IMI is a unique Public-Private Partnership (PPP) between the pharmaceutical industry represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Union represented by the European Commission.
Other Positions
Clinical Research Fellow
Department/Division/Faculty Department of Surgery and Cancer / Division of Surgery / Pain Research

Salary Range: £31,383 - £39,693 per annum plus London Weighting allowance (£1,505 per annum)

Chelsea & Westminster Campus

The Fellow will conduct clinical research by deep phenotyping of patients with diabetic polyneuropathy, under the supervision of Prof. Andrew Rice (Professor of Pain Research, Imperial College).

The post is funded by the European Commission (Horizon 2020-PHC1-2014) as part of the major multicentre project DOLORisk: Understanding risk factors and determinants for neuropathic pain. DOLORisk is led by Prof. David Bennett (Professor of Neurology and Neurobiology, Oxford University) and involves active collaboration with world leading neurology, genetics, psychology and primary care academic units in Oxford and Dundee and also in Sweden, Denmark, Israel, Germany, Belgium and France.

The role includes recruitment, assessment and deep profiling of diabetic patients for features of peripheral polyneuropathy. The Fellow will be trained in cutting edge symptom, quantitative sensory, electrophysiological and psychological profiling techniques. The Fellow will be required to archive and analyse data and to process samples for genotyping. A high level of interaction with those involved in the genetics aspects of DOLORisk is required.

You should be medically qualified and have full GMC registration (or eligibility for such). It is essential that you are confident and skilled in practical clinical procedures. Applications are especially welcomed from doctors with experience in a relevant clinical speciality (e.g. neurology, clinical neurophysiology, diabetes and endocrinology, primary care, pain medicine etc).

You should have good written and verbal communication skills, analytical and problem solving abilities and have proven ability to manage projects, work to deadlines and collaborate with others. Research experience and a record of peer reviewed publications are highly desirable, but not essential.

Arrangements will be made for you to hold honorary contract with Chelsea & Westminster NHS Foundation Trust. You will be expected to enrol in Imperial College’s PhD programme, unless, exceptionally you already possess a PhD or equivalent. This is a full time research post, there will be no fixed clinical duties and you are not required to participate in any on-call rota. You will however be encouraged to participate in clinical activities in order to maintain and develop your clinical skills.

This is a full time post, fixed-term for 3 years and will be based at Chelsea & Westminster Campus.

Should you have any informal queries please contact: Professor Andrew Rice, email: a.rice@imperial.ac.uk

Closing Date

31 August 2015 (midnight BST)

How To Apply

Our preferred method of application is online via this website. Please download the following application form and save to your computer. Once completed, please upload your application form prior to submitting your application.

Please note that CVs should only be submitted for Academic posts and must be accompanied by an application form. For all other posts, including Research and Administrative and Support posts, please submit an application form only, unless requested otherwise.

Click here for more info